Section of Urology, Saint Peter's Cancer Care Center, Albany, NY 12208, USA; Department of Surgery, Albany Medical College, Albany, NY 12208, USA.

A Phase I/II trial was conducted to assess the radiosensitizer docetaxel administered weekly (20 mg/m(2)) with concurrent intensity modulated radiation therapy (72 Gy at 1.8 Gy/fraction) in high risk prostate cancer.

Patients with high risk prostate cancer (clinical stage >/=T3; Gleason score 8, 9, or 10; Gleason score 7 and PSA > 10) received IMRT (Clinac 600 CD with 6 MV photons and sliding window technique) and concurrent weekly docetaxel (20 mg/m(2)) as a continuous 30 minute infusion for 8 weeks. Patients desirous of concurrent androgen suppression were not excluded.

Twenty men (median age: 64 years; range, 50-78 years) were enrolled in the chemoradiation protocol. Three patients experienced treatment interruptions: dehydration requiring inpatient hydration (n = 2); NSAID induced GI bleed (n = 1). An additional patient required outpatient hydration (<24 hours) with no treatment interruption. Overall, the most frequently observed toxicities were grade 2 diarrhea (40%), grade 2 fatigue (40%), grade 2 urinary frequency (35%), taste aversion (20%), grade 2 constipation (20%), and rectal bleeding (15%). No significant hematologic toxicity (grades 2-4) was encountered among the 20 patients. Although the follow-up interval was relatively short, no significant subacute gastrointestinal toxicities have been observed. At a median follow-up duration of 11.7 months, 17 patients were free of biochemical disease recurrence, and all patients are alive.

The radiosensitizer docetaxel administered weekly (20 mg/m(2)) with concurrent IMRT is well tolerated with acceptable toxicity. Early oncologic outcomes in this challenging patient cohort are encouraging.

Written by
Perrotti M, Doyle T, Kumar P, McLeod D, Badger W, Prater S, Moran M, Rosenberg S, Bonatsos C, Kreitner C, Kiehl R, Chang T, Kolodziej M.

Reference
Urol Oncol. 2008 May-Jun;26(3):276-80.
doi:10.1016/j.urolonc.2007.04.003

PubMed Abstract
PMID:18452819

UroToday.com Prostate Cancer Section

Please log-in or register in order to submit comments.

Powered by AkoComment!